Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Keros Therapeutics, Inc. | 10%+ Owner | Common Stock | 1.23M | $55.5M | $45.29 | Nov 29, 2022 | Indirect |
Eloxx Pharmaceuticals, Inc. | 10%+ Owner | Common Stock | 617K | $444K | $0.72 | May 13, 2021 | By Pontifax Investment Fund |
Keros Therapeutics, Inc. | 10%+ Owner | Call Options (obligation to sell) | 0 | Nov 29, 2022 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
KROS | Keros Therapeutics, Inc. | Nov 29, 2022 | 6 | -$1 | 4 | Nov 30, 2022 | 10%+ Owner |
ELOX | Eloxx Pharmaceuticals, Inc. | May 13, 2021 | 4 | $8M | 4 | May 17, 2021 | 10%+ Owner |
KROS | Keros Therapeutics, Inc. | Apr 7, 2020 | 0 | $0 | 3/A | Nov 30, 2022 | 10%+ Owner |